BR112019006129A2 - derivados de tetra-hidropiridina e seu uso como agentes antibacterianos - Google Patents

derivados de tetra-hidropiridina e seu uso como agentes antibacterianos

Info

Publication number
BR112019006129A2
BR112019006129A2 BR112019006129A BR112019006129A BR112019006129A2 BR 112019006129 A2 BR112019006129 A2 BR 112019006129A2 BR 112019006129 A BR112019006129 A BR 112019006129A BR 112019006129 A BR112019006129 A BR 112019006129A BR 112019006129 A2 BR112019006129 A2 BR 112019006129A2
Authority
BR
Brazil
Prior art keywords
bacterial infections
compounds
methods
negative bacterial
gram
Prior art date
Application number
BR112019006129A
Other languages
English (en)
Inventor
Park Cheon-Hyoung
Cho Chong-Hwan
Moon Ho-Sang
Sung Hyun-Jung
Lee Hyung-Keun
Choi Ji-Hoon
Kim Jin-Hyuk
Moon Jun-Hwan
Park Jung-Sang
Lee Min-Jung
Song Seung-Hyun
Choi Sun-Ho
Choi Sung-Hak
Im Weon-Bin
Kim Yoon-Jung
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of BR112019006129A2 publication Critical patent/BR112019006129A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente revelação se refere a um composto de derivado de tetra-hidropiridina inovador, um estereoisômero do mesmo ou um sal farmaceuticamente aceitável do mesmo, métodos para preparar os compostos, métodos para inibir udp-3-o-(r-3-hidroximiristoil)-n-acetilglicosamina desacetilase (lpxc), métodos para tratar infecções bacterianas gram-negativas, uso dos compostos para a preparação de medicamentos terapêuticos para tratar infecções bacterianas gram-negativas, e composições farmacêuticas para prevenção ou tratamento de infecções bacterianas gram-negativas, que contêm os compostos. os compostos representados pela fórmula i, estereoisômeros do mesmo ou sais farmaceuticamente aceitáveis do mesmo de acordo com o presente revelação podem exibir efeitos excelentes no tratamento de infecções bacterianas.
BR112019006129A 2016-09-28 2017-09-28 derivados de tetra-hidropiridina e seu uso como agentes antibacterianos BR112019006129A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662400694P 2016-09-28 2016-09-28
PCT/KR2017/010896 WO2018062924A1 (en) 2016-09-28 2017-09-28 Tetrahydropyridine derivatives and their use as antibacterial agents

Publications (1)

Publication Number Publication Date
BR112019006129A2 true BR112019006129A2 (pt) 2019-06-18

Family

ID=61687790

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006129A BR112019006129A2 (pt) 2016-09-28 2017-09-28 derivados de tetra-hidropiridina e seu uso como agentes antibacterianos

Country Status (15)

Country Link
US (1) US10160724B2 (pt)
EP (1) EP3519387B1 (pt)
JP (1) JP6812542B2 (pt)
KR (1) KR102264248B1 (pt)
CN (1) CN110088087B (pt)
AU (1) AU2017337946B2 (pt)
BR (1) BR112019006129A2 (pt)
CA (1) CA3037118C (pt)
ES (1) ES2891025T3 (pt)
MX (1) MX2019003585A (pt)
PL (1) PL3519387T3 (pt)
PT (1) PT3519387T (pt)
RU (1) RU2722594C1 (pt)
WO (1) WO2018062924A1 (pt)
ZA (1) ZA201901945B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7268049B2 (ja) 2018-03-08 2023-05-02 インサイト・コーポレイション PI3K-γ阻害剤としてのアミノピラジンジオール化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311201D0 (en) * 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7879911B2 (en) * 2007-02-01 2011-02-01 Johnson Alan T Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
CA2774250C (en) * 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
EP2694481B1 (en) * 2011-04-08 2015-12-30 Pfizer Inc Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
SG193367A1 (en) * 2011-04-08 2013-10-30 Pfizer Isoxazole derivatives useful as antibacterial agents
WO2013170165A1 (en) * 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
EP3134401B1 (en) * 2014-04-22 2018-06-13 Novartis AG Isoxazoline hydroxamic acid derivatives as lpxc inhibitors
EP3143007B1 (en) 2014-05-16 2018-07-11 Idorsia Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
RU2018124788A (ru) * 2015-12-08 2020-01-15 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Замещенные бензазиноны в качестве антибактериальных соединений

Also Published As

Publication number Publication date
ES2891025T3 (es) 2022-01-25
AU2017337946B2 (en) 2020-05-07
PT3519387T (pt) 2021-09-28
WO2018062924A1 (en) 2018-04-05
PL3519387T3 (pl) 2022-02-07
EP3519387A1 (en) 2019-08-07
JP2019534252A (ja) 2019-11-28
KR102264248B1 (ko) 2021-06-14
ZA201901945B (en) 2022-07-27
EP3519387B1 (en) 2021-08-11
EP3519387A4 (en) 2020-05-13
MX2019003585A (es) 2019-06-10
NZ751511A (en) 2020-11-27
RU2722594C1 (ru) 2020-06-02
CN110088087B (zh) 2022-08-09
US10160724B2 (en) 2018-12-25
US20180086709A1 (en) 2018-03-29
CN110088087A (zh) 2019-08-02
KR20190047127A (ko) 2019-05-07
CA3037118A1 (en) 2018-04-05
JP6812542B2 (ja) 2021-01-13
CA3037118C (en) 2021-12-14
AU2017337946A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
BR112022025037A2 (pt) Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
BR112018010962A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto.
BR112016023679A2 (pt) derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos
BR112020006381A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
BR112018015289A2 (pt) compostos de benzopirazol e análogos dos mesmos
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112014015845A8 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
BR112018011670A2 (pt) compostos antibacterianos
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]